

Determinants and effectiveness of BNT162b2 mRNA vaccination among patients with atopic dermatitis: A population-based study

Khalaf Kridin MD, PhD^{1,2,3}; Yochai Schonmann MD, MSc^{4,5}; Erez Onn MD, HA^{2,6};

Tamar Leshem PhD^{1,2}; Dana Tzur Bitan PhD^{7,8}; Orly Weinstein MD, MPH^{4,5*};

Arnon D. Cohen MD, MPH, PhD^{4,5*}

1. Unit of Dermatology and Skin Research Laboratory, Baruch Padeh Poria Medical Center, Israel
2. Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
3. Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
4. Clalit Health Services, Tel-Aviv, Israel
5. Faculty of Health Sciences, Ben-Gurion University of the Negev, Ben-Gurion Ave, Beer Sheva, Israel
6. Baruch Padeh Medical Center, Poriya, Israel
7. Department of Behavioral Sciences, Ariel University, Ariel, Israel
8. Shalvata Mental Health Center, Hod Hasharon, affiliated with the Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel

* Both authors contributed equally.

Corresponding Author:

Dr. Khalaf Kridin

Lübeck Institute of Experimental Dermatology

University of Lübeck

Ratzeburger Allee 160

23562 Lübeck, Germany

Email: dr_kridin@hotmail.com

Supplementary Table - The risk of COVID-19 among fully-vaccinated patients with AD treated by immunosuppressive drugs and phototherapy as compared to those without these treatment modalities.

	COVID-19 infection		COVID-19 infection	
	Fully-vaccinated on immunosuppressive drugs during the pandemic (N=398)	Fully-vaccinated without immunosuppressive drugs during the pandemic (N=42,035)	Fully-vaccinated on phototherapy during the pandemic (N=285)	Fully-vaccinated without phototherapy during the pandemic (N=42,148)
Follow-up time, PY	162.0	16,552.6	116.0	16,598.6
Median follow-up time, months (range)	5.0 (1.2-5.5)	4.8 (0.2-5.5)	5.0 (2.8-5.5)	4.8 (0.2-5.5)
Number of events	1	103	1	103
Incidence rate / 1000 PY (95% CI)	6.2 (0.31-30.4)	6.2 (5.1-7.5)	8.6 (0.4-42.5)	6.2 (5.1-7.5)
Unadjusted HR (95% CI) [P value]	1.01 (0.14-7.22) [0.994]	Reference	1.41 (0.20-10.07) [0.735]	Reference
Fully adjusted HR (95% CI) [P value]^a	0.95 (0.13-6.81) [0.985]	Reference	1.28 (0.18-9.18) [0.807]	Reference

^a-Multivariate logistic regression model adjusting for age, sex, ethnicity, cardiovascular diseases, metabolic syndrome, COPD, CRF, malignancy, smoking

Abbreviations: n, Number; PY, person-year; HR, hazard ratio; CI, confidence interval; NA, non-applicable

Bold: significant value